Biotron Limited · ASX:BIT
Biotron — Australasian Life Science Investment Summit (October 2010)
8 slides from Biotron's conference presentation, Oct 20, 2010
Slide 1: Presentation to Investors (ASX cover letter)
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au For personal use only Website: www.biotron.com.au 20 October 2010 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (8 pages by email) Dear Madam PRESENTATION TO
Slide 2: Novel Small-Molecule Antiviral Drugs
For personal use only ASX BIT ASX:BIT Novel Small-Molecule Antiviral Drugs Michelle Miller, CEO mmiller@biotron com au mmiller@biotron.com.au
Slide 3: Biotron Ltd Overview
Biotron Ltd Overview For personal use only • Established in 1999 as a spin-out p from the Australian National University, y Canberra; Based in Sydney, Australia • IPO on ASX in Jan 2001 (Ticker code BIT) • Focus on developing novel small molecule antiviral drugs • Hep C, HIV, Dengue • Key highlights
Slide 4: Biotron's Pipeline
Biotron’s Biotron s Pipeline For personal use only • Two clinical phase programs: – Hepatitis C virus (BIT225) and HIV Clinical Trials Project j Target g Discoveryy Preclinical Phase Ia Ph Ib Ph IIa Hep C p7 HIV Vpu Dengue M protein Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au
Slide 5: Lead Product – BIT225
Lead Product – BIT225 For personal use only BIT225 is a new investigational g oral drug g in development p for treating g Hep pC infection Completed two clinical trials: Phase Ia – Placebo-Controlled, Randomized Study of the Safety and Pharmacokinetics of BIT225 in Healthy Volunteers (48 patie
Slide 6: BIT225 Clinical Information
BIT225 Clinical Information For personal use only First-in-class drug targeting p7 protein of Hep C virus p7 - Critical role in production of infectious Hep C virus in infected cells Proposed as new target for therapeutic intervention Phase Ia results indicated that BIT225 was well-tolerated
Slide 7: BIT225 – Commercialization Strategy
BIT225 – Commercialization Strategy For personal use only • Hep C worldwide market ~US$2.8 billion; predicted to expand to >US$10 billion • Over 170 million individuals infected causing severe liver disease, including cirrhosis and hepatocellular carcinoma • Low response rate L t due d tto complianc
Slide 8: Capital Structure
Capital p Structure For personal use only Shares on issue 121.8 m Listed options 108 m Unlisted options 6.4 m Cash at 30 June10 A$1.78 m Current market cap A$12 8 m A$12.8 Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au Biotron Limited
Biotron — Australasian Life Science Investment Summit (October 2010) on 6ix